Latest Regulatory Clearance News

Arovella Therapeutics has secured TGA confirmation to advance its Phase 1 trial of ALA-101 in Australia via the efficient Clinical Trial Notification pathway, following FDA clearance in the US.

Orthocell has appointed LEDA Orthopaedics as the exclusive distributor for its Remplir™ nerve repair product in the UK, positioning itself for a rapid commercial launch pending regulatory approval.

Pan African Resources has agreed to acquire Emmerson Resources via a scheme of arrangement valued at approximately A$311 million, offering Emmerson shareholders a 36.4% premium. The deal aligns interests in the Tennant Creek Joint Venture and provides exposure to a larger gold producer.

Nova Minerals has signed a Scheme Implementation Deed to redomicile to the US, aiming for a primary NYSE listing while retaining a secondary ASX listing via CDIs. The move seeks to align corporate structure with its Alaskan operations and enhance access to US capital markets.

Magellan Financial Group has successfully raised $130 million through an institutional placement to support its strategic merger with Barrenjoey Capital Partners, with a $20 million share purchase plan also announced for existing shareholders.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

ClearView Wealth Limited has entered a definitive scheme implementation deed with Zurich Financial Services Australia Limited, agreeing to a $415 million acquisition at a 21.5% premium to its recent share price. The deal, supported by major shareholders and subject to regulatory and court approvals, offers shareholders a cash consideration of 65 cents per share plus potential dividends and ticking fees.

Lumos Diagnostics has hit a key enrollment milestone in its BARDA-funded paediatric study for FebriDx®, unlocking a US$720,000 payment and edging closer to FDA expansion.

Bindi Metals has secured regulatory approval to commence its maiden drilling program at the Ravni Gold Project in Serbia, while historic drill core resampling is underway with assay results expected soon.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.

Austral Resources has executed binding agreements to acquire the Lady Loretta mine from Glencore and plans to repay its Rocklands Facility debt, positioning itself as a debt-free copper producer with enhanced financial flexibility.

Clarity Pharmaceuticals’ Cu-64 SAR-bisPSMA diagnostic agent significantly outperformed the current standard Ga-68 PSMA-11 in detecting prostate cancer recurrence, more than doubling lesion and patient detection rates in a pivotal head-to-head trial.